Literature DB >> 26288695

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

Xiaojing Wang1, Minghua Sun1, Connie New1, Spencer Nam1, Wesley P Blackaby1, Alastair J Hodges1, David Nash1, Mizio Matteucci1, Joseph P Lyssikatos1, Peter W Fan1, Suzanne Tay1, Jae H Chang1.   

Abstract

Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very challenging. Strategies to mitigate TDI are therefore highly valuable in discovering safe therapies to benefit patients. In this Letter, we disclose our simplified approach toward addressing CYP3A TDI liabilities, guided by metabolic mechanism hypotheses. By adding a methyl group onto the α carbon of a basic amine, TDI activities of both the truncated and full molecules (7a and 11) were completely eliminated. We propose that truncated molecules, albeit with caveats, may be used as surrogates for full molecules to investigate TDI.

Entities:  

Keywords:  CYP3A; Pim kinases; TDI; metabolic mechanism

Year:  2015        PMID: 26288695      PMCID: PMC4538442          DOI: 10.1021/acsmedchemlett.5b00191

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

1.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

2.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

3.  CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs.

Authors:  Alfred Zimmerlin; Markus Trunzer; Bernard Faller
Journal:  Drug Metab Dispos       Date:  2011-03-07       Impact factor: 3.922

4.  Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.

Authors:  Austin Chen; Daniel Dubé; Laurence Dubé; Sébastien Gagné; Michel Gallant; Mireille Gaudreault; Erich Grimm; Robert Houle; Patrick Lacombe; Sébastien Laliberté; Suzanna Liu; Dwight MacDonald; Bruce Mackay; David Martin; Dan McKay; David Powell; Jean-François Lévesque
Journal:  Bioorg Med Chem Lett       Date:  2010-07-11       Impact factor: 2.823

Review 5.  Drug-drug interaction studies: regulatory guidance and an industry perspective.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Christopher Gibson; Donghui Cui; Ka Lai Yee; Jeanine Ballard; Tamara Cabalu; Jerome Hochman
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

6.  Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.

Authors:  Paul A Barsanti; Robert J Aversa; Xianming Jin; Yue Pan; Yipin Lu; Robert Elling; Rama Jain; Mark Knapp; Jiong Lan; Xiaodong Lin; Patrick Rudewicz; Janet Sim; Lorena Taricani; George Thomas; Linda Xiao; Qin Yue
Journal:  ACS Med Chem Lett       Date:  2014-11-20       Impact factor: 4.345

7.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.

Authors:  Gabriele Cruciani; Emanuele Carosati; Benoit De Boeck; Kantharaj Ethirajulu; Claire Mackie; Trevor Howe; Riccardo Vianello
Journal:  J Med Chem       Date:  2005-11-03       Impact factor: 7.446

Review 8.  Summary of information on human CYP enzymes: human P450 metabolism data.

Authors:  Slobodan Rendic
Journal:  Drug Metab Rev       Date:  2002 Feb-May       Impact factor: 4.518

9.  Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

Authors:  Alessandro A Boezio; Loren Berry; Brian K Albrecht; David Bauer; Steven F Bellon; Christiane Bode; April Chen; Deborah Choquette; Isabelle Dussault; Mei Fang; Satoko Hirai; Paula Kaplan-Lefko; Jay F Larrow; Min-Hwa Jasmine Lin; Julia Lohman; Michele H Potashman; Yusheng Qu; Karen Rex; Michael Santostefano; Kavita Shah; Roman Shimanovich; Stephanie K Springer; Yohannes Teffera; Yajing Yang; Yihong Zhang; Jean-Christophe Harmange
Journal:  Bioorg Med Chem Lett       Date:  2009-09-27       Impact factor: 2.823

10.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Authors:  Shufeng Zhou; Eli Chan; Xiaotian Li; Min Huang
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

View more
  1 in total

1.  The Dark Side of Fluorine.

Authors:  Yue Pan
Journal:  ACS Med Chem Lett       Date:  2019-06-20       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.